Monopar Therapeutics Inc. Share Price
MNPRMonopar Therapeutics Inc. Stock Performance
Open $56.76 | Prev. Close $56.13 | Circuit Range N/A |
Day Range $56.76 - $57.96 | Year Range $26.05 - $103.77 | Volume 3,315 |
Average Traded $57.46 |
Monopar Therapeutics Inc. Share Price Chart
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
09-Apr-26 | $56.76 | $57.75 | +0.00% |
09-Apr-26 | $56.76 | $57.75 | +11.91% |
07-Apr-26 | $52.00 | $51.60 | -3.05% |
06-Apr-26 | $56.84 | $53.23 | -3.66% |
02-Apr-26 | $56.11 | $55.25 | -0.96% |
01-Apr-26 | $56.07 | $55.78 | +1.43% |
31-Mar-26 | $56.60 | $55.00 | +2.27% |